158 related articles for article (PubMed ID: 37704352)
21. MEK inhibitors in RASopathies.
Bergqvist C; Wolkenstein P
Curr Opin Oncol; 2021 Mar; 33(2):110-119. PubMed ID: 33395032
[TBL] [Abstract][Full Text] [Related]
22. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
23. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK; Johnson M; Thornburg L; Halford Z
Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
[TBL] [Abstract][Full Text] [Related]
24. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
[TBL] [Abstract][Full Text] [Related]
25. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
[TBL] [Abstract][Full Text] [Related]
26.
Chaney KE; Perrino MR; Kershner LJ; Patel AV; Wu J; Choi K; Rizvi TA; Dombi E; Szabo S; Largaespada DA; Ratner N
Cancer Res; 2020 Nov; 80(21):4720-4730. PubMed ID: 32816910
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
[TBL] [Abstract][Full Text] [Related]
28. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
[TBL] [Abstract][Full Text] [Related]
30. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
31. Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1.
Mateos ME; López-Laso E; Vicente J; Ortega R; Vázquez F; Pérez-Navero JL
Pediatr Int; 2020 Jul; 62(7):857-859. PubMed ID: 32027426
[No Abstract] [Full Text] [Related]
32. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
[TBL] [Abstract][Full Text] [Related]
33. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.
Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L
Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177
[TBL] [Abstract][Full Text] [Related]
34. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
[TBL] [Abstract][Full Text] [Related]
35. Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.
Karaosmanoglu B; Kocaefe ÇY; Söylemezoğlu F; Anlar B; Varan A; Vargel İ; Ayter S
Childs Nerv Syst; 2018 May; 34(5):877-882. PubMed ID: 29455242
[TBL] [Abstract][Full Text] [Related]
36. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
[TBL] [Abstract][Full Text] [Related]
37. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
[TBL] [Abstract][Full Text] [Related]
38. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
40. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]